Literature DB >> 12939418

GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody.

K Kaida1, S Kusunoki, K Kamakura, K Motoyoshi, I Kanazawa.   

Abstract

BACKGROUND: The authors previously reported that immunoglobulin G (IgG) antibody to the ganglioside N-acetylgalactosaminyl GD1a (GalNAc-GD1a) is associated with the pure motor variant of Guillain-Barré syndrome (GBS). Elucidation of the localization of GalNAc-GD1a in human peripheral nerve tissue may lead to understanding of the pathogenetic role of anti-GalNAc-GD1a antibody in GBS.
METHODS: IgG anti-GalNAc-GD1a-monospecific antibody was purified from anti-GalNAc-GD1a antibody-positive rabbit sera through an affinity column. Anti-neurofilament-200 monoclonal and anti-HNK-1 monoclonal antibodies were used as the markers for axon and myelin. Immunohistochemical study using double fluorescence labeling technique was conducted in human ventral roots (VR), dorsal roots (DR), intramuscular nerves, and sural nerves. Human teased ventral fibers also were studied.
RESULTS: Anti-GalNAc-GD1a antibody immunostained an inner part of compact myelin and additionally a periaxonal-axolemma-related portion in the VR, small-diameter DR fibers, and IM nerves. In sural nerves, small fibers were selectively stained. In VR, the staining was localized in the paranodal region.
CONCLUSION: Anti-GalNAc-GD1a antibodies in patients' sera may bind to those regions in the VR and IM nerves where GalNAc-GD1a is localized, and may function in the pathogenesis of pure motor type GBS. Further investigation is needed to explain the discrepancy between the immunolocalization of GalNAc-GD1a in sensory nerves and the absence of sensory disturbance in patients with GBS with IgG anti-GalNAc-GD1a antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12939418     DOI: 10.1212/01.wnl.0000081229.88862.c6

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Subacute motor axonal neuropathy associated with the IgG anti-GalNAc-GD1a antibody.

Authors:  Hirofumi Goto; Takayasu Fukudome; Susumu Kusunoki; Hidenori Matsuo
Journal:  BMJ Case Rep       Date:  2011-03-29

2.  Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants.

Authors:  Michiaki Koga; Masaki Takahashi; Keiko Yokoyama; Takashi Kanda
Journal:  J Neurol       Date:  2015-06-09       Impact factor: 4.849

Review 3.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

4.  Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Authors:  Jun Ueda; Hajime Yoshimura; Nobuo Kohara
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

5.  Sporadic Amyotrophic Lateral Sclerosis Due to a FUS P525L Mutation with Asymmetric Muscle Weakness and Anti-ganglioside Antibodies.

Authors:  Masanobu Tanemoto; Shin Hisahara; Kazuna Ikeda; Kazuki Yokokawa; Tatsuo Manabe; Reiko Tsuda; Daisuke Yamamoto; Takashi Matsushita; Akihiro Matsumura; Syuuichirou Suzuki; Shun Shimohama
Journal:  Intern Med       Date:  2021-02-01       Impact factor: 1.271

6.  Ion Mobility Mass Spectrometry Reveals Rare Sialylated Glycosphingolipid Structures in Human Cerebrospinal Fluid.

Authors:  Mirela Sarbu; Dragana Fabris; Željka Vukelić; David E Clemmer; Alina D Zamfir
Journal:  Molecules       Date:  2022-01-24       Impact factor: 4.411

Review 7.  Autoimmune Peripheral Neuropathies and Contribution of Antiganglioside/Sulphatide Autoantibody Testing.

Authors:  Dirk Roggenbuck; Emilien Delmont; Dirk Reinhold; Peter Schierack; Karsten Conrad; Joseph Boucraut
Journal:  Mediterr J Rheumatol       Date:  2020-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.